BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BC Extra | Oct 1, 2019
Company News

Oct. 1 Company Quick Takes: NVS, Microsoft to use AI for drug R&D; plus AstraZeneca, Tmunity-CHOP and AGTC-Otonomy deals

Novartis, Microsoft partner on AI for drug R&D  Novartis AG (NYSE:NVS; SIX:NOVN) is partnering with Microsoft Corp. (NASDAQ:MSFT) to use artificial intelligence for drug development, with an initial focus on personalized macular degeneration therapies, cell...
BC Extra | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

Locana Inc. (San Diego, Calif.) hired Kathie Bishop as CSO to succeed acting CSO Gene Yeo, who co-founded the company and chairs its SAB. Bishop was CSO at Otonomy Inc. (NASDAQ:OTIC) and previously held roles...
BC Week In Review | Mar 16, 2018
Clinical News

FDA approves label expansion for Otonomy's Otiprio

Otonomy Inc. (NASDAQ:OTIC) said FDA approved an sNDA for Otiprio ciprofloxacin to treat acute otitis externa due to Pseudomonas aeruginosa or Staphylococcus aureus infection in patients ages six months and older. Otiprio is a sustained-release...
BC Extra | Mar 12, 2018
Company News

Management tracks: WuXi NextCode, Assembly

WuXi NextCode Genomics Inc. (Cambridge, Mass.) said CEO Hannes Smárason is stepping down. He is succeeded by EVP and COO Rob Brainin. Last year, the genomics company raised $240 million in a series B round...
BC Extra | Dec 28, 2017
Company News

Management tracks: Vivus, Peregrine

Cardiovascular, metabolic and pulmonary company Vivus Inc. (NASDAQ:VVUS) said CEO Seth Fischer will step down. Thomas King, a director, will serve as interim CEO as the company seeks a permanent replacement. King was president and...
BC Week In Review | Nov 30, 2017
Clinical News

Otonomy's Meniere’s disease candidate meets in Phase III

Otonomy Inc. (NASDAQ:OTIC) reported top-line data from the double-blind, European Phase III AVERTS-2 trial in 174 patients with unilateral Meniere’s disease showing that a single 12 mg intratympanic injection of Otividex dexamethasone (OTO-104) met the...
BC Week In Review | Sep 1, 2017
Clinical News

Otonomy's Meniere’s disease candidate misses in Phase III

Otonomy Inc. (NASDAQ:OTIC) reported data from the double-blind, U.S. Phase III AVERTS-1 trial in 165 patients with unilateral Meniere’s disease who were experiencing 4 to 22 days with definitive vertigo episodes of >20 minutes showing...
BC Extra | Aug 30, 2017
Clinical News

Otonomy falls after Phase III Meniere’s disease failure

Otonomy Inc. (NASDAQ:OTIC) plummeted $17.22 (83%) to $3.58 after it said Otividex dexamethasone (OTO-104) missed the primary endpoint in the U.S. Phase III AVERTS-1 study to treat unilateral Meniere’s disease. The company, which lost $521.8...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
Items per page:
1 - 10 of 117
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BC Extra | Oct 1, 2019
Company News

Oct. 1 Company Quick Takes: NVS, Microsoft to use AI for drug R&D; plus AstraZeneca, Tmunity-CHOP and AGTC-Otonomy deals

Novartis, Microsoft partner on AI for drug R&D  Novartis AG (NYSE:NVS; SIX:NOVN) is partnering with Microsoft Corp. (NASDAQ:MSFT) to use artificial intelligence for drug development, with an initial focus on personalized macular degeneration therapies, cell...
BC Extra | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

Locana Inc. (San Diego, Calif.) hired Kathie Bishop as CSO to succeed acting CSO Gene Yeo, who co-founded the company and chairs its SAB. Bishop was CSO at Otonomy Inc. (NASDAQ:OTIC) and previously held roles...
BC Week In Review | Mar 16, 2018
Clinical News

FDA approves label expansion for Otonomy's Otiprio

Otonomy Inc. (NASDAQ:OTIC) said FDA approved an sNDA for Otiprio ciprofloxacin to treat acute otitis externa due to Pseudomonas aeruginosa or Staphylococcus aureus infection in patients ages six months and older. Otiprio is a sustained-release...
BC Extra | Mar 12, 2018
Company News

Management tracks: WuXi NextCode, Assembly

WuXi NextCode Genomics Inc. (Cambridge, Mass.) said CEO Hannes Smárason is stepping down. He is succeeded by EVP and COO Rob Brainin. Last year, the genomics company raised $240 million in a series B round...
BC Extra | Dec 28, 2017
Company News

Management tracks: Vivus, Peregrine

Cardiovascular, metabolic and pulmonary company Vivus Inc. (NASDAQ:VVUS) said CEO Seth Fischer will step down. Thomas King, a director, will serve as interim CEO as the company seeks a permanent replacement. King was president and...
BC Week In Review | Nov 30, 2017
Clinical News

Otonomy's Meniere’s disease candidate meets in Phase III

Otonomy Inc. (NASDAQ:OTIC) reported top-line data from the double-blind, European Phase III AVERTS-2 trial in 174 patients with unilateral Meniere’s disease showing that a single 12 mg intratympanic injection of Otividex dexamethasone (OTO-104) met the...
BC Week In Review | Sep 1, 2017
Clinical News

Otonomy's Meniere’s disease candidate misses in Phase III

Otonomy Inc. (NASDAQ:OTIC) reported data from the double-blind, U.S. Phase III AVERTS-1 trial in 165 patients with unilateral Meniere’s disease who were experiencing 4 to 22 days with definitive vertigo episodes of >20 minutes showing...
BC Extra | Aug 30, 2017
Clinical News

Otonomy falls after Phase III Meniere’s disease failure

Otonomy Inc. (NASDAQ:OTIC) plummeted $17.22 (83%) to $3.58 after it said Otividex dexamethasone (OTO-104) missed the primary endpoint in the U.S. Phase III AVERTS-1 study to treat unilateral Meniere’s disease. The company, which lost $521.8...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
Items per page:
1 - 10 of 117